StreetInsider.com News Articles

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

Thu, 23 Jul 2026 16:10:00 -0400

ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results will be released on Thursday, August 6, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

Thu, 23 Jul 2026 16:10:00 -0400

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

Thu, 23 Jul 2026 16:10:00 -0400

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

Thu, 23 Jul 2026 16:10:00 -0400

Artivion (AORT) Reiterated at Market Outperform by Citizens on AMDS Prosthesis Growth

Tue, 21 Jul 2026 04:41:24 -0400

Citizens analyst Daniel Stauder reiterated a Market Outperform rating and $48.00 price target on Artivion Inc. (NYSE: AORT).

The analyst commented, "We reiterate our Market Outperform rating and $48 price target on shares of Artivion. The AMDS Hybrid Prosthesis platform had been a growth driver over the past several quarters, however, on its 1Q26 call, management reported slower-than-anticipated initial stocking orders at new accounts—leading to a lowering of FY26 guidance, putting downward pressure on the stock. AMDS received FDA PMA approval in late June and had been available under an HDE designation through FY25. One of the primary dynamics causing the

Needham on Artivion Inc. (AORT): 'we believe our thesis remains intact'

Mon, 20 Jul 2026 05:58:44 -0400

Needham analyst Mike Matson reiterated a Buy rating and $44.00 price target on Artivion Inc. (NYSE: AORT).

The analyst comments "Given the decline in AORT's share price, which was driven by the 1Q26 guidance reduction, we are revisiting our thesis. AORT is in the early stages of a major product cycle driven by its AMDS (launched in early 2025) and NEXUS (launch in early 2027) products that we expect to drive revenue growth back into the low-teens or better and adjusted EBITDA growth of 20%+ in 2027E and 2028E. We believe that the issues that drove the guidance reduction are temporary

Canaccord Reiterates Buy Rating on Artivion Inc. (AORT)

Mon, 29 Jun 2026 09:12:27 -0400

Canaccord analyst William Plovanic reiterated a Buy rating and $36.00 price target on Artivion Inc. (NYSE: AORT).

The analyst commented: "This morning, Artivion announced that its AMDS Hybrid Prosthesis received FDA premarket approval. The approval supports marketing for acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion. Artivion estimates that this indication represents 60% of all Debakey Type I aortic dissection, which impacts ~6,000 U.S. patients annually, and is an emergent, life-threatening, surgery-requiring condition. Additionally, the approval also broadens AMDS’ label from the Humanitarian Device Exemption (“HDE” -see more below); previously, under the HDE, AMDS was only indicated

FDA approves Artivion's AMDS device for aortic dissection treatment

Mon, 29 Jun 2026 07:02:17 -0400

Artivion, Inc. (NYSE: AORT) announced that the U.S. Food and Drug Administration has approved the premarket approval application (PMA) for its AMDS Hybrid Prosthesis, a device used in the treatment of acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion.

The approval covers an estimated 60% of all DeBakey Type I aortic dissection cases. With the PMA in place, hospitals will no longer need to obtain institutional review board approval before implanting the device, a requirement that had been tied to its prior Humanitarian Device Exemption status.

The PMA is based on data from the PERSEVERE U.S. IDE trial, which

FDA approves Artivion's AMDS device for aortic dissection treatment

Mon, 29 Jun 2026 07:02:17 -0400

The PMA is based on data from the PERSEVERE U.S. IDE trial, which

FDA approves Artivion's AMDS device for aortic dissection treatment

Mon, 29 Jun 2026 07:02:17 -0400

The PMA is based on data from the PERSEVERE U.S. IDE trial, which

FDA approves Artivion's AMDS device for aortic dissection treatment

Mon, 29 Jun 2026 07:02:17 -0400

The PMA is based on data from the PERSEVERE U.S. IDE trial, which

Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis